CHK1/2 inhibition has been extensively explored clinically in various cancer types but not yet in GB, likely because numerous CHK1/2i were discontinued before phase III, such as UCN-01 (7-hydroxystaurosporine), rabusertib (LY2603618) and MK-8776 (SCH 900776) [162,163,164,165,166,167,168]. Here, CHEK1 is linked to cancer.